Jan 20 | News
Total investment of roughly EUR 35 million / Efficient and flexible production of HDI and IPDI / Rising demand for high-performance polyurethane automotive coatings
|
Jan 19 | News
Watson Pharmaceuticals, Inc. has announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.
|
Jan 17 | News
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)
|
Dec 22 2011 | News
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy
|
Dec 20 2011 | News
Home for orphans in Tohoku region / Bayer’s relief aid to Japan totals almost EUR 2.3 million
|
Dec 20 2011 | News
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to...
|
Dec 20 2011 | News
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again
|
Dec 14 2011 | News
Once approved, the new low dose IUS will offer young women contraception for up to three years
|
Dec 8 2011 | News
Patients receiving VEGF Trap-Eye 2mg every other month achieved visual acuity gains similar to ranibizumab with, on average, five fewer injections over two years / Patients who required the most intense therapy, on average, received 1.4 fewer injections in the VEGF Trap-Eye 2mg every...
|
Nov 30 2011 | News
Watson Pharmaceuticals reported Tuesday that U.S. regulators cleared the company's oral contraceptive product Vestura, which is a generic version of Bayer's Yaz (drospirenone/ethinyl estradiol).
|